Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
The market for C-reactive protein (CRP) testing has experienced significant growth recently, fueled by rising awareness and expanded applications in healthcare diagnostics. This sector is poised for continued expansion as advances in technology and increasing demand for early disease detection drive further adoption across various medical settings. Below is an in-depth overview of the market size, key growth drivers, major players, and emerging trends shaping the future of CRP testing.
Market Size and Growth Forecast for the C-Reactive Protein Testing Market
The value of the c-reactive protein testing market has seen steady growth, rising from $3.52 billion in 2025 to $3.7 billion in 2026, which corresponds to a compound annual growth rate (CAGR) of 5.1%. This positive momentum during the historical period stems from factors such as the growing prevalence of inflammatory diseases, increased utilization of CRP testing in clinical diagnostics, expanded hospital lab infrastructure, heightened awareness of early disease detection, and the availability of standardized assay kits. Looking ahead, the market is projected to reach $4.48 billion by 2030, maintaining a CAGR of 4.9%. This upcoming growth phase is driven by rising demand for point-of-care inflammatory testing, greater integration of automated diagnostic platforms, expansion of preventive health screening programs, broader adoption of high-throughput laboratory systems, and the increasing focus on personalized medicine diagnostics. Among the key trends expected to influence the market are the growing use of high-sensitivity CRP assays, automated immunoassay systems, rapid inflammation diagnostic tools, expanded CRP testing for cardiovascular risk assessment, and enhanced laboratory workflow automation.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6719&type=smp
Factors Fueling Growth in the C-Reactive Protein Testing Market
One of the primary growth catalysts for the CRP testing market is the increasing incidence of cardiovascular diseases (CVD). These diseases encompass various heart conditions, including diseased blood vessels, structural heart problems, and blood clots. While the exact causes of CVD remain complex, lifestyle-related behavioral risk factors such as poor diet, physical inactivity, smoking, and alcohol consumption contribute to the buildup of fatty deposits in arteries (atherosclerosis), which increases the likelihood of blood clots. These behaviors also lead to elevated blood pressure, glucose levels, blood lipids, weight gain, and obesity. As CVD cases rise, there is a heightened need for CRP testing to assist in diagnosing or predicting cardiovascular risk, offering a comparable measure to cholesterol levels. For example, in October 2024, data from the US Centers for Disease Control revealed that in 2023, cardiovascular diseases were responsible for about 919,032 deaths in the United States alone, representing nearly one-third of all deaths. This alarming statistic underscores why the growing prevalence of cardiovascular conditions is a key driver in the expansion of the CRP testing market.
Detailed Segmentation Analysis of the C-Reactive Protein Testing Market
The c-reactive protein testing market is categorized into several segments to better understand its growth areas:
1) By Assay Type:
– Enzyme-Linked Immunosorbent Assay (ELISA)
– Chemiluminescence Immunoassay (CLIA)
– Immunoturbidimetric Assays
2) By Application:
– Diabetes
– Rheumatoid Arthritis
– Cardiovascular Disease
– Inflammatory Bowel Disease
– Cancer
– Other Applications
3) By End Use:
– Clinics
– Hospitals
– Diagnostic Laboratories
Further subcategories include specific assay techniques such as Direct ELISA, Indirect ELISA, and Sandwich ELISA under the ELISA segment; Luminometer-Based and Automated CLIA Systems within CLIA; and Nephelometry-Based and Latex Agglutination Immunoturbidimetric Assays. This detailed segmentation helps clarify the areas where demand is expanding and technological advancements are focused.
Access The Complete C-Reactive Protein Testing Market Report:
https://www.thebusinessresearchcompany.com/report/c-reactive-protein-testing-global-market-report
Innovations Driving Transformation in the C-Reactive Protein Testing Market
Leading companies in the CRP testing space are emphasizing technological innovation, particularly through the development of high-sensitivity automated immunoassays. These cutting-edge tools enable the accurate and rapid detection of very low levels of CRP, which is crucial for early cardiovascular risk assessment and real-time inflammation monitoring. High-sensitivity automated immunoassays use refined immunoturbidimetric or nephelometric methods to detect CRP concentrations that fall well below those measurable by standard assays, allowing for earlier clinical intervention and better prognostic evaluations. For instance, in January 2024, Siemens Healthineers introduced the Atellica CH High Sensitivity C-Reactive Protein 2 (hCRP2) assay for their Atellica CH Analyzer. This assay utilizes two ready-to-use reagent packs—one with a phosphate buffer and surfactant, and the other containing monoclonal anti-CRP antibodies bound to polystyrene particles. The presence of CRP causes these particles to aggregate, and the system measures light scattering intensity proportional to CRP concentration. Designed for use with serum or plasma samples, this assay delivers fast, quantitative results to support timely clinical decisions in cardiovascular risk stratification.
Key Players Leading the C-Reactive Protein Testing Industry
Several prominent companies hold significant positions in the CRP testing market, driving both innovation and market growth. These include Thermo Fisher Scientific Inc., F Hoffmann-La Roche AG, Danaher Corporation, Quest Diagnostics Incorporated, Siemens AG, Abbott Laboratories, Aidian Oy, Boditech Med Inc., Horiba Ltd., Laboratory Corporation, Merck KGAA, Randox Laboratories Limited, Getein Biotech Inc., Bio-Rad Laboratories Inc., DiaSorin S.p.A., Eurofins Scientific SE, Inova Diagnostics Inc., Luminex Corporation, Sekisui Diagnostics LLC, Sysmex Corporation, Tosoh Corporation, Trinity Biotech Plc, WerfenLife Group LLC, ZEUS Scientific Inc., BioMérieux SA, Biomerica Inc., Gold Standard Diagnostics Corp., Immunodiagnostic Systems Holdings PLC, and Nova Biomedical Corporation. Their ongoing research and product development efforts are central to advancing CRP testing capabilities.
Geographical Insights and Regional Market Opportunities for CRP Testing
In 2025, North America dominated the c-reactive protein testing market in terms of size. Nonetheless, the fastest expansion is anticipated in the Asia-Pacific region during the forecast period. The market report covers key regions including Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, offering a comprehensive global perspective on market dynamics and growth prospects.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
